New pill aims to tame rare blood cancers in early trial

NCT ID NCT07612280

First seen Jun 05, 2026 · Last updated Jun 17, 2026 · Updated 4 times

Summary

This study tests an experimental daily pill, JBI-802, in about 30 adults with certain blood cancers (MPN or MDS/MPN) that cause too many platelets. The goal is to check safety and see if the drug can lower platelet counts and shrink the cancer. Participants take the pill for up to 2 years, with regular checkups and tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hollywood Private Hospital

    RECRUITING

    Nedlands, 6009, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Macquarie University

    RECRUITING

    Sydney, New South Wales, 2109, Australia

  • Monash Medical Centre

    RECRUITING

    Melbourne, Victoria, 3168, Australia

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • St Vincent's Hospital (Melbourne)

    RECRUITING

    Melbourne, Victoria, 3065, Australia

  • St. Vincent's Hospital Sydney Limited

    RECRUITING

    Sydney, New South Wales, 2010, Australia

  • The Perth Blood Institute Limited

    RECRUITING

    Perth, Western Australia, 6000, Australia

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.